emi Targeting the STING pathway as a cancer immunotherapy

The STING pathway is part of the innate immune system. Activation of STING spontaneously or via exogenous agents can elicit strong antitumor immunity. This project aims to develop novel therapeutics that activate STING in the tumor microenvironment for improved control of tumors and metastases.